You're invited to join UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences for the 2025 Adrenal Symposium happening Saturday, Feb. 22, 2025, from 8:30 a.m. to 4:30 p.m. EST. This course is designed to cover the most recent advances in the diagnosis and treatment of #adrenal disorders, including the management of incidental adrenal nodules. William F. Young, Jr., MD, MSc, Mayo Clinic College of Medicine and Science, will be the keynote speaker. ?? More Details: https://lnkd.in/eM8X8ntA
UPMC Hillman Cancer Center
医院和医疗保健
Pittsburgh，Pennsylvania 4,840 位关注者
UPMC Hillman Cancer Center is a premier National Cancer Institute-designated Comprehensive Cancer Center.
关于我们
UPMC Hillman Cancer Center (formerly the University of Pittsburgh Cancer Institute) is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center affiliated with the University of Pittsburgh. The mission of UPMC Hillman Cancer Center is to provide the highest level of clinical care to the 110,000 patients treated at its facilities each year while performing cutting-edge research and educating the next generation of cancer researchers and physicians. At Hillman, we are quickly advancing the latest research discoveries into pioneering therapies that can benefit our patients throughout our integrated cancer care delivery network.
- 网站
-
https://hillmanresearch.upmc.edu/
UPMC Hillman Cancer Center的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 5,001-10,000 人
- 总部
- Pittsburgh，Pennsylvania
- 类型
- 非营利机构
- 领域
- Cancer Research和Cancer Care
地点
-
主要
获取路线
5115 Centre Ave
US，Pennsylvania，Pittsburgh，15232
UPMC Hillman Cancer Center员工
-
Monica Baskin
Professor; Assoc Dir of Community Outreach and Engagement and Health Equity of UPMC Hillman Cancer Center; Asst Vice Chancellor University of…
-
Terri Frassinelli, DNP, RN, OCN?
Clinical Director, UPMC Hillman Cancer Centers
-
Susan Radio
Program Director, Oncology Outreach and Education
-
Pritish Iyer
Oncologist at UPMC
动态
-
Jeremy Rich, MD, MHS, MBA, Announced as Interim Director Dr. Rich will lead UPMC Hillman Cancer Center during its transition with Robert Ferris, MD, PhD’s?departure on the horizon. Dr. Rich, who joined UPMC Hillman in early 2021, is a board-certified?neuro-oncologist and renowned physician-scientist. More at: https://lnkd.in/eBaW-3Jw
Jeremy Rich, MD, MHS, MBA, Announced Interim Director - UPMC Hillman Cancer Center
hillmanresearch.upmc.edu
-
Register for UPMC Hillman Cancer Center's Multidisciplinary Thyroid Cancer Symposium happening Saturday, Nov. 16, 2024, from 8:30 a.m. to 4:30 p.m. EST. Hear from keynote speakers, Sarah Mayson, MD, and Michael W. Yeh, MD, FACS, about the most recent advances in the therapy of benign and malignant thyroid diseases: https://lnkd.in/ex9C5M2v
-
-
New radiation oncology #CME from UPMC Hillman Cancer Center ?? Tyler Wilhite, MD, discusses how to better recognize the role of low-dose radiation therapy (LDRT) in the management of osteoarthritis, design appropriate radiotherapy target volumes for #osteoarthritis, and analyze patient outcomes by following recommended treatment techniques for LDRT. Earn credit today: https://lnkd.in/ezGkzs7N
Low Dose Radiation Therapy for Arthritis | UPMC
-
Proud to have two of our UPMC Hillman docs helping to shape the future of immunotherapy!
The Society for Immunotherapy of Cancer (SITC)’s latest manuscript, “Society for Immunotherapy of Cancer recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease” is now available in the Journal for ImmunoTherapy of Cancer. Dive into expert guidance on trial optimization to better demonstrate efficacy of intratumoral immunotherapies. Find guidance on a variety of design elements including: - Patient stratification factors - Exclusion criteria - Study arm considerations - Optimal endpoints - Response assessments - Patient populations to prioritize View manuscript: https://lnkd.in/gDfBw-3N Thank you to the members of the Intratumoral Immunotherapy Clinical Trials Expert Panel, Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Diwakar Davar, MD, MS, UPMC Hillman Cancer Center, Aurélien Marabelle, MD, PhD, Gustave Roussy, Robert Andtbacka, MD, CM, FACS, FRCSC, HiFiBiO Therapeutics, Bhardwaj Nina, MD, PhD, The Icahn School of Medicine at Mount Sinai, Joshua Brody, MD, The Icahn School of Medicine at Mount Sinai, Jason Chesney, MD, PhD, University of Louisville, Robert Coffin, PhD, Replimune, Thierry de Baere, MD, PhD, Gustave Roussy, Tanja de Gruijl, PhD, Amsterdam University Medical Centers, Matthew Fury, MD, Regeneron Pharmaceuticals, Inc., Greg Goldmacher, MD, PhD, MBA, Merck, Kevin J. Harrington, BSc, MBBS, MRCP, FRCR, FRCP, PhD, DIC, The Royal Marsden - Private Care, Howard Kaufman, MD, Ankyra Therapeutics, Ciara M. Kelly, Memorial Sloan Kettering Cancer Center, Anuradha D Khilnani, MD, Merck, Ke Liu , MD, PhD, Marengo Therapeutics, Sherene Loi, MD, PhD, Peter MacCallum Cancer Centre, Georgina V. Long, MBBS, PhD, BSc, FRAC, University of Sydney Ignacio Melero, MD, PhD, University of Navarra, Mark Middleton, MD, PhD, University of Oxford, Bart Neyns, MD, PhD, Universitair Ziekenhuis Brussel David James Pinato, MD, MRes, PhD, Imperial College London Rahul A. Sheth, MD, The University of Texas MD Anderson Cancer Center Stephen Solomon, MD, Memorial Sloan Kettering Cancer Center and Philippe Szapary MD, MSCE, Johnson & Johnson.
-
-
We congratulate all our oncologists who were recognized as “Top Doctors” this year by Pittsburgh Magazine. See who made the 2024 list https://lnkd.in/eTbiSC4J
-
-
Our director Robert Ferris has been involved with #SITC for more than two decades. Proud to have him in the election for the next VP of this important organization!
The 2024 SITC Election is now open! #SITC members are electing the society’s next Vice President and three At-Large Directors. The election closes on Thursday, May 16 at 11:59 p.m. EDT. https://lnkd.in/gx3DgRwP
-
Congratulations to Bennett Van Houten for being elevated to the rank #AAASFellow by the American Association for the Advancement of Science (AAAS)! Becoming a AAAS Fellow is among the highest distinctions in the scientific community. This program honors scientists, engineers, and innovators whose efforts are scientifically or socially distinguished. Dr. Van Houten is recognized for “outstanding contributions to the field of DNA damage and repair, particularly the development of several novel methods for understanding the choreography of the DNA repair processes.” Read more: https://lnkd.in/gB_6hHDD
-
-
On March 19, the PA Breast Cancer Coalition (PBCC) presented two $100,000 research grants to UPMC breast cancer researchers Julia Foldi, MD, PhD, assistant professor of Medicine, and Shandong Wu, PhD, associate professor of Radiology. The event was held in UPMC Hillman Cancer Center’s Atrium Lobby. To date, the PA Breast Cancer Coalition has contributed $1.5 million to UPMC cancer research. Dr. Foldi studies behaviors of invasive lobular breast cancer (ILC), the second most common type of breast cancer. ILC has a higher rate of recurrence after five years than invasive ductal breast cancer (IDC), another common type. Her team will use PBCC funding to focus on determining why patients with ILC have a greater risk of late metastasis in the hopes of developing targeted therapies and possible recurrence prevention measures in the future. Dr. Wu’s PBCC-funded research focuses on breast cancer screening techniques. In conjunction with previous PBCC research grant winner Dr. Wendie Berg, Dr. Wu studies contrast-enhanced mammography (CEM), a more effective modality than traditional mammography, which includes injecting contrast or dye through an IV into the patient to view clearer images of the breast tissue. CEM is preferred by many patients over breast MRI; however, it produces a high rate of false positives. Dr. Wu plans to utilize artificial intelligence to create new software aimed at distinguishing normal findings from abnormalities in CEM screenings.
-
-
Researchers led by Anwaar Saeed, MD, published results from the CAMILLA trial showing that combining cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer is a promising treatment, potentially expanding treatment options. The CAMILLA trial’s promising results have led to the phase III STELLAR 303 trial investigating the combination of zanzalintinib — a next generation multi-kinase inhibitor very similar to cabozantinib — and atezolizumab. Led by Dr. Saeed, this trial will help guide further innovative strategies for combinational ICI-based treatments to challenge the status quo of colorectal cancer immunotherapy options. https://lnkd.in/eWGEg6iv
-